LY03003 clinical trials
Also written LY03003.
How each study uses LY03003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY03003
- 6
Studies by the year they started
10 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Luye Pharma Group Ltd. (9) · Peking University Third Hospital (1)
Studies
Open first, then newest update. How each study uses LY03003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PDCompletedPhase 1Luye Pharma Group Ltd.NCT04630860Written as LY03003How we know
- A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PDCompletedPhase 3Luye Pharma Group Ltd.NCT04571164Written as LY03003(Rotigotine,extended-release microspheres)How we know
- A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproCompletedPhase 1Luye Pharma Group Ltd.NCT03733561Written as LY03003How we know
- A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD PatientsCompletedPhase 1Luye Pharma Group Ltd.NCT04629404Written as LY03003How we know
- A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003CompletedPhase 1Luye Pharma Group Ltd.NCT04627155Written as LY03003How we know
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersCompletedPhase 1Luye Pharma Group Ltd.NCT04384666Written as LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)How we know
- A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's DiseaseCompletedPhase 1Luye Pharma Group Ltd.NCT04045678Written as LY03003 ( Rotigotine, extended-release microspheres)How we know
- Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's DiseaseCompletedPhase 3Peking University Third HospitalNCT04455555Written as LY03003( the name of rotigotine)How we know
- Pharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseCompletedPhase 1Luye Pharma Group Ltd.NCT03589066Written as LY03003How we know
- Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseCompletedPhase 1Luye Pharma Group Ltd.NCT02055274Written as LY03003How we know